HQ Team
September 12, 2023: Nuvectis Pharma, Inc., a US biopharmaceutical firm, has started its experimental trial in humans to treat solid tumors.
The study is designed to evaluate the safety, tolerability and pharmacokinetic properties of the experimental drug NXP900 in patients with advanced solid tumors, according to a company statement.
The trial will focus on the inhibitor NXP900 belonging to the Src family kinases (SFKs) — which are key regulators of cell proliferation, differentiation, and survival.
A kinase is an enzyme that moves something from one molecule to another. It literally means “an enzyme to move.”
72 FDA approvals
Kinase inhibitors serve as a potential target for treating various diseases like autoimmune disorders, cardiovascular diseases, cancer, and inflammatory disorders.
As of November 24, 2022, the USFDA had approved 72 small molecules that are therapeutic protein kinase inhibitors.
Nuvectic’s first inhibitor drug, NXP800, an oral small molecule currently in a Phase 1b clinical trial investigating its potential to treat platinum-resistant, ARID1a-mutated ovarian carcinoma, was granted Fast Track Designation by the FDA.
“Advancing NXP900 into its first in human clinical trial is an important milestone for Nuvectis,” said Ron Bentsur, Co-Founder, Chairman and Chief Executive Officer of Nuvectis, a New Jersey-based company.
‘Potential to be first’
“We believe that NXP900’s unique mechanism of action, which completely shuts down signalling via SFK, in conjunction with its high target specificity, differentiates it from other multi-kinase inhibitors that also inhibit SFK and provide it with the potential to become the first SFK inhibitor for the treatment of solid tumours.”
Ovarian cancer often goes undetected until it has spread within the pelvis and stomach. At this late stage, ovarian cancer is more difficult to treat and can be fatal.
Ovarian cancer often has no symptoms in the early stages. Later stages are associated with symptoms, but they can be non-specific, such as loss of appetite and weight loss.
Surgery and chemotherapy are generally used to treat ovarian cancer.
Fifth in cancer deaths
According to the American Cancer Society estimates for ovarian cancer in the United States in 2023 about 19,710 women will receive a new diagnosis of ovarian cancer about 13,270 women will die from it.
Ovarian cancer ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of the female reproductive system.
A woman’s risk of getting ovarian cancer during her lifetime is about 1 in 78. Her lifetime chance of dying from ovarian cancer is about 1 in 108. This cancer mainly develops in older women.
